Predicting blood cancer progression with genetic analysis
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with MGUS, smoldering myeloma, or active multiple myeloma
- You do not have an active infection or autoimmune disease
- If you can become pregnant, you must be able to rule out pregnancy
- You have not used high-dose steroids in the last week
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
This trial is testing a new type of blood test (called a liquid biopsy) to find multiple myeloma early by looking at tiny pieces of DNA in your blood. It is for people already diagnosed with multiple myeloma, smoldering multiple myeloma, or MGUS.
This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.
This study uses a special label (carbon 13) to track bone marrow cells in people with a pre-cancer condition called MGUS. It aims to learn how these cells work, which may help understand the condition better.
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
This study tries to predict which people at higher risk will develop myeloma (a blood cancer) and how quickly. It may help doctors spot problems earlier in people with family history and offer better follow-up.
Hear when a new Monoclonal Gammopathy of Undetermined Significance (MGUS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.